B Merck News Today

Drugmaker Merck & Co. filed a lawsuit Tuesday alleging President Biden's marquee effort to negotiate down the cost of drugs under Medicare is "tantamount to extortion" and violates the Constitution.

Johnson & Johnson reportedly shut down the only plant making usable batches of its COVID-19 vaccine even though many poor and developing nations are relying on the shots to immunize their populations.

Johnson & Johnson reportedly shut down the only plant making usable batches of its COVID-19 vaccine even though many poor and developing nations are relying on the shots to immunize their populations.

A panel of U.S. health advisers on Tuesday narrowly backed the benefits of a closely watched COVID-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans could take at home to treat the virus.

Federal health regulators say an experimental COVID-19 pill from Merck is effective against the virus, but they will seek input from outside experts on risks of birth defects and other potential problems in pregnant women.

Federal health regulators say an experimental COVID-19 pill from Merck is effective against the virus, but they will seek input from outside experts on risks of birth defects and other potential problems in pregnant women.

The European Medicines Agency said it has received a request from Merck to authorize its coronavirus antiviral, the first pill shown to treat COVID-19.

The European Medicines Agency said it has received a request from Merck to authorize its coronavirus antiviral, the first pill shown to treat COVID-19.

Britain has granted a conditional authorization to Merck's coronavirus antiviral, the first pill shown to successfully treat COVID-19. It is the first country to OK the treatment, although it was not immediately clear how quickly the pill would be available.

Vaccines are the focus of the global fight against COVID-19, but a flurry of therapeutic breakthroughs and fights over a limited supply of antibody drugs are returning treatments back to the spotlight.